ATE510540T1 - Thioxanthen-derivate als alleinvertreter der antiinfektiva zur verwendung in der behandlung von infektionskrankheiten - Google Patents

Thioxanthen-derivate als alleinvertreter der antiinfektiva zur verwendung in der behandlung von infektionskrankheiten

Info

Publication number
ATE510540T1
ATE510540T1 AT08700129T AT08700129T ATE510540T1 AT E510540 T1 ATE510540 T1 AT E510540T1 AT 08700129 T AT08700129 T AT 08700129T AT 08700129 T AT08700129 T AT 08700129T AT E510540 T1 ATE510540 T1 AT E510540T1
Authority
AT
Austria
Prior art keywords
treatment
infectious diseases
infectives
thioxanthene derivatives
exclusive
Prior art date
Application number
AT08700129T
Other languages
English (en)
Inventor
Birgit Giwercman
Original Assignee
Bkg Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bkg Pharma Aps filed Critical Bkg Pharma Aps
Application granted granted Critical
Publication of ATE510540T1 publication Critical patent/ATE510540T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Dairy Products (AREA)
AT08700129T 2007-01-05 2008-01-07 Thioxanthen-derivate als alleinvertreter der antiinfektiva zur verwendung in der behandlung von infektionskrankheiten ATE510540T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/DK2007/000006 WO2008080398A1 (en) 2007-01-05 2007-01-05 Anti - infective agents such as phenothiazine and thioxanthene derivates to treat infectious diseases
PCT/DK2008/000005 WO2008080408A1 (en) 2007-01-05 2008-01-07 Thioxanthene derivates usefulto treat infectious diseases

Publications (1)

Publication Number Publication Date
ATE510540T1 true ATE510540T1 (de) 2011-06-15

Family

ID=37914358

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08700129T ATE510540T1 (de) 2007-01-05 2008-01-07 Thioxanthen-derivate als alleinvertreter der antiinfektiva zur verwendung in der behandlung von infektionskrankheiten

Country Status (17)

Country Link
US (1) US20100113430A1 (de)
EP (2) EP2114406B1 (de)
JP (2) JP5399921B2 (de)
CN (1) CN101594869B (de)
AT (1) ATE510540T1 (de)
AU (1) AU2008203743B2 (de)
CA (1) CA2673809C (de)
CY (1) CY1111778T1 (de)
DK (1) DK2114406T3 (de)
EA (1) EA016886B1 (de)
ES (1) ES2367151T3 (de)
HR (1) HRP20110607T1 (de)
MX (1) MX2009007235A (de)
NZ (1) NZ577821A (de)
PL (1) PL2114406T3 (de)
PT (1) PT2114406E (de)
WO (2) WO2008080398A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008080398A1 (en) * 2007-01-05 2008-07-10 Bkg Pharma Aps Anti - infective agents such as phenothiazine and thioxanthene derivates to treat infectious diseases
EP2246349A1 (de) * 2009-04-20 2010-11-03 BKG Pharma ApS Behandlung von Infektionskrankheiten
CN103172591B (zh) * 2013-03-13 2014-07-30 陕西科技大学 含吩噻嗪基的Schiff碱类化合物及其制备方法和应用
CN103709122B (zh) * 2013-11-29 2016-05-25 四川大学 用于治疗的抗肿瘤和抗真菌化合物
AU2017279905B2 (en) * 2016-06-23 2021-10-14 Bioimics Ab Anti-infective heterocyclic compounds and uses thereof
CN112353805A (zh) * 2020-11-17 2021-02-12 北京化工大学 氟哌噻吨在治疗和预防柯萨奇病毒感染中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE578983A (de) 1958-05-29
DE1518325B1 (de) 1960-03-07 1970-08-27 Smith Kline French Lab Basisch substituierte Trifluormethylxanthene und deren nicht toxische Saeureadditionssalze und Verfahren zu deren Herstellung
GB1453828A (en) * 1972-12-08 1976-10-27 Kefalas As Fluoro-substituted thiaxanthene derivatives
US4407800A (en) * 1981-11-02 1983-10-04 University Of Virginia Alumni Patents Foundation Protozoacidal activity of phenothiazines
AU625071B2 (en) * 1988-04-20 1992-07-02 Merrell Dow Pharmaceuticals Inc. N-alkylamino derivatives of aromatic, tricyclic compounds in the treatment of drug-resistant protozoal infections
US20020151543A1 (en) * 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
FR2813792B1 (fr) * 2000-09-12 2003-03-14 Inst Necker Moyens pour la regulation des defenses immunitaires
US6569853B1 (en) 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
ES2739852T3 (es) 2001-07-06 2020-02-04 Veloxis Pharmaceuticals As Aglomeración controlada
US20030229082A1 (en) * 2002-01-16 2003-12-11 The Regents Of The University Of California Inhibition of RNA function
US20060193788A1 (en) * 2002-11-26 2006-08-31 Hale Ron L Acute treatment of headache with phenothiazine antipsychotics
AU2003205543A1 (en) 2003-01-14 2004-08-10 Lifecycle Pharma A/S Dry dispersions
KR20060066722A (ko) * 2003-08-13 2006-06-16 쿠도스 파마슈티칼스 리미티드 아미노피론 및 ａｔｍ억제제로서의 이의 용도
MXPA06012566A (es) * 2004-04-30 2007-05-09 Bkg Pharma Aps Tratamiento de enfermedades infecciosas.
WO2006094207A2 (en) * 2005-03-03 2006-09-08 St. Jude Children's Research Hospital Substituted phenoxazines and acridones as inhibitors of akt
WO2008080398A1 (en) * 2007-01-05 2008-07-10 Bkg Pharma Aps Anti - infective agents such as phenothiazine and thioxanthene derivates to treat infectious diseases
EP2246349A1 (de) * 2009-04-20 2010-11-03 BKG Pharma ApS Behandlung von Infektionskrankheiten

Also Published As

Publication number Publication date
CN101594869A (zh) 2009-12-02
CA2673809A1 (en) 2008-07-10
PT2114406E (pt) 2011-08-25
JP2010514814A (ja) 2010-05-06
AU2008203743A1 (en) 2008-07-10
EA016886B1 (ru) 2012-08-30
EA200970663A1 (ru) 2009-12-30
JP2013173752A (ja) 2013-09-05
NZ577821A (en) 2012-07-27
PL2114406T3 (pl) 2011-10-31
WO2008080408A1 (en) 2008-07-10
EP2114406B1 (de) 2011-05-25
JP5399921B2 (ja) 2014-01-29
CY1111778T1 (el) 2015-10-07
CN101594869B (zh) 2013-08-07
MX2009007235A (es) 2009-10-16
EP2301545A1 (de) 2011-03-30
WO2008080398A1 (en) 2008-07-10
HK1139309A1 (en) 2010-09-17
CA2673809C (en) 2013-08-13
DK2114406T3 (da) 2011-09-12
US20100113430A1 (en) 2010-05-06
AU2008203743B2 (en) 2012-07-12
EP2114406A1 (de) 2009-11-11
HRP20110607T1 (hr) 2011-09-30
ES2367151T3 (es) 2011-10-28

Similar Documents

Publication Publication Date Title
ATE447559T1 (de) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
ATE439863T1 (de) Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie
EP2111223A4 (de) Aminderivatverbindungen zur behandlung von augenerkrankungen und -leiden
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
ATE541832T1 (de) Neuartige p2x7r-antagonisten und ihre verwendung
EA200802213A1 (ru) Способы лечения заболеваний крови
ECSP109882A (es) Derivados de 1-cianociclopropilo como inhibidores de la catepsina k
EP2101785A4 (de) Behandlung von trockenem auge
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
ATE494926T1 (de) Neuartige p2x7r-antagonisten und ihre verwendung
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
EP2141989A4 (de) Zusammensetzungen und verfahren zur vorbeugung und behandlung von suchtkrankheiten
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE555116T1 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
CY1111778T1 (el) Παραγωγα θειοξανθενιου ως μοναδικοι αντιμολυσματικοι παραγοντες για χρηση στην αντιμετωπιση των μολυσματικων ασθενειων
ATE464895T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
EA200701995A1 (ru) Способы уменьшения кальцификации

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2114406

Country of ref document: EP